Compare Stocks

→ Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol-Myers Squibb	$48.86 -0.3%	$51.22	$47.58 ▼ $70.93	$99.03B	0.39	15.53 million shs	16.03 million shs

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol-Myers Squibb	-0.28%	+1.51%	-5.64%	-2.47%	-30.54%

Pentagon contract could send this $2 AI stock soaring (Ad)

Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...

Get all the info here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol-Myers Squibb	4.5887 of 5 stars	2.1	5.0	3.3	4.0	2.4	1.7	1.9

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol-Myers Squibb	2.11	Hold	$61.18	25.21% Upside

Current Analyst Ratings

Latest BMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/18/2024	BMY Bristol-Myers Squibb	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$51.00 ➝ $52.00
4/1/2024	BMY Bristol-Myers Squibb	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/11/2024	BMY Bristol-Myers Squibb	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
2/6/2024	BMY Bristol-Myers Squibb	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$58.00 ➝ $51.00
2/6/2024	BMY Bristol-Myers Squibb	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$77.00 ➝ $54.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol-Myers Squibb	$45.01B	2.20	$12.40 per share	3.94	$14.49 per share	3.37

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol-Myers Squibb	$8.03B	$3.86	12.66	6.91	1.48	17.83%	50.95%	16.67%	4/25/2024 (Confirmed)

Latest BMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/25/2024	N/A	BMY Bristol-Myers Squibb	-$4.5050	N/A	+$4.5050	N/A	N/A	N/A
2/2/2024	12/31/2023	BMY Bristol-Myers Squibb	$1.55	$1.70	+$0.15	$2.53	$11.19 billion	$11.48 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol-Myers Squibb	$2.40	4.91%	+8.20%	62.18%	N/A

Latest BMY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/1/2024	BMY Bristol-Myers Squibb	quarterly	$0.60	4.72%	4/4/2024	4/5/2024	5/1/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol-Myers Squibb	1.24	1.43	1.31

Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol-Myers Squibb	76.41%

Insider Ownership

Company	Insider Ownership
BMY Bristol-Myers Squibb	0.09%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol-Myers Squibb	34,100	2.03 billion	2.02 billion	Optionable

BMY Headlines

Source	Headline
	Bristol-Myers Squibb (NYSE:BMY) Stock Price Down 0.7% marketbeat.com - April 24 at 5:17 PM
	Yousif Capital Management LLC Sells 19,824 Shares of Bristol-Myers Squibb (NYSE:BMY) marketbeat.com - April 24 at 4:00 PM
	Bristol-Myers Earnings Preview: Major near-term headwinds invites worries about Q1 results msn.com - April 24 at 2:59 PM
	Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold? zacks.com - April 24 at 1:06 PM
	What's in Store for These 5 Pharma Bigwigs in Q1 Earnings? zacks.com - April 24 at 10:21 AM
	Q3 2024 EPS Estimates for Bristol-Myers Squibb (NYSE:BMY) Lowered by Analyst marketbeat.com - April 24 at 6:32 AM
	Bristol-Myers Squibb (NYSE:BMY) Shares Up 0.2% marketbeat.com - April 23 at 3:20 PM
	New York State Common Retirement Fund Decreases Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) marketbeat.com - April 23 at 12:28 PM
	Bristol-Myers Squibb gets grant for humanized antibodies binding CD40 for treatment of CD40-related diseases pharmaceutical-technology.com - April 23 at 10:16 AM
	Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Illinois Municipal Retirement Fund marketbeat.com - April 22 at 9:59 PM
	California Public Employees Retirement System Sells 56,653 Shares of Bristol-Myers Squibb (NYSE:BMY) marketbeat.com - April 22 at 6:59 PM
	Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know zacks.com - April 22 at 3:01 PM
	Bristol-Myers Squibb (NYSE:BMY) Stock Price Up 0.8% marketbeat.com - April 22 at 2:53 PM
	Bristol Myers, Cellares ink $380M CAR-T therapies supply deal msn.com - April 22 at 12:36 PM
	Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics zacks.com - April 22 at 10:21 AM
	Is Bristol Myers Squibb A Buy At These Bottom Levels? seekingalpha.com - April 22 at 9:30 AM
	Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies reuters.com - April 22 at 7:23 AM
	Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster businesswire.com - April 22 at 6:59 AM
	Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster businesswire.com - April 22 at 6:59 AM
	Keeler Thomas Management LLC Has $2.18 Million Holdings in Bristol-Myers Squibb (NYSE:BMY) marketbeat.com - April 21 at 11:27 PM
	Is Bristol-Myers Squibb (NYSE:BMY) Using Too Much Debt? finance.yahoo.com - April 21 at 9:19 AM
	Golcadomide hydrochloride by Bristol-Myers Squibb for Non-Hodgkin Lymphoma: Likelihood of Approval pharmaceutical-technology.com - April 21 at 1:53 AM
	Capital Management Corp VA Cuts Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) marketbeat.com - April 20 at 7:04 PM
	Golcadomide hydrochloride by Bristol-Myers Squibb for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval pharmaceutical-technology.com - April 20 at 5:43 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bristol-Myers Squibb

NYSE:BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial